Curriculum vitae

Proposed role in the project: Principal Investigator

  1. First name: MohsenMiddle: Mohamed Family: Fathallah
  2. Date of birth:12-8-1955
  3. Nationality: Egyptian
  4. Education:MBBCH.Degree with grad very good with honour 1979

Institution
[ Date from - Date to ] / Degree(s) or Diploma(s) obtained:
1994 / PhD. Clinical Pharmacology , Marbery, Germany
1986 / PhD. Medical Microbiology , Zürich, Switzerland
1984 / Licentiate of Arts, psychology dept. 1984
1979 / MBBCH. Degree, Ain Shams University, Egypt
  1. Language skills: Indicate competence on a scale of 1 to 5 (1 - excellent; 5 - basic)

Language / Reading / Speaking / Writing
English / Excellent (1) / Excellent (1) / Excellent (1)
Germany / Elementary (4) / Elementary (4) / Elementary (4)
  1. Membershipof professional bodies: ACRP (Association of Clinical Research Professional)
  2. Other Skills: working knowledge of windows and Microsoft office (Excel, Word and Power Point ) as well as Internet and E-mail ( Outlook and others)
  3. Present Position:CEO & Managing Director / Principal Investigator in Genuine Research Center 2007 to date.
  4. Key Qualifications: PhD clinical pharmacology / Medical.
  5. Specific International Experience:

Country / Service Activity / Date from - Date to
Germany / Clinical drug development / Fab., 92- Sept., 2000
Switzerland / Clinical microbiology / Sept., 84- August 86
  1. ProfessionalExperience

Date from - Date to / Country / Company Served / Position/Assignment / Description
2000-2006 / Egypt / Genuine Pharma / CEO &Managing Director / Training &Development
1996-2000 / Egypt / Hoechst Marion Russell / Medical Manager
1992-1996 / Egypt / Hoechst Marion Russell / Local Monitor
1982-1992 / Egypt / Faculty of Medicine, Ain Shams University / Associate Professor of Medical Microbiology
1980-1982 / Egypt / Faculty of Medicine, Ain Shams University / GP & House-officer
  1. Other Relevant Information (e.g. Publications)
  • 2001, National drug policy, MOHP &WHO (EMRO).
  • 2004, implementing drug management on national level, MOPH & WHO (EMRO).
  • 2004, Loxoprofen Na in low back pain, BMJ.
  • 2005, Rosiglitazone in type 2 DM, Egyptian experience, BMJ.
  • 2006, Egyptian national formulary, MOHP & WHO (EMRO).
  • 2006, Clopidogrel in coronary heart disease, BMJ.
  • 2006, Guidelines for good prescribing practice, MOHP & WHO (EMRO).
  • 2007, National policy for assessments of herbal products, MOHP & WHO (EMRO).
  • 2009, Elshafeey AH, Kamel AO, Fathallah MM. Utility of Nanosized Microemulsion for Transdermal Delivery of Tolterodine Tartrate: Ex-Vivo Permeation and In-Vivo Pharmacokinetic Studies. Pharm Res. 2009 Aug 21. [Epub ahead of print]
  • 2009, A.H. Elshafeey , M. Elsherbiny, M.M Fathallah; A Single-Dose, A single-dose, randomized, two-way crossover study comparing two olanzapine tablet products in healthy adult male volunteers under fasting conditions Clinical Therapeutics,Vol 31, No 3, 2009.
  1. TRANING
  • Good Clinical Practice –Duke University Health System June 2011.
  • ACRP Global conference, Seattle, WA May 2010.
  • ACRP Global conference, Tampa, FL May 2011.
  • Effective presentation skills by AUC in Cairo, 1998.
  • Clinical Development in Pharma industry, Oxford-group-Paris/France 1996.

The following topics were covered during the course:

-Pharmaceutical industry (economic, social and legal environment).

-Drug development, pre-clinical.

-Clinical trial phase I to IV.

-Drug regulatory affairs.

-GCP guidelines, European, ICH and FDA. Drug safety.

-Quality assurance.

  • Training on medical direction in Pharma industry, Medical Dept. VPI, Hoechst AG-Frankfurt/Germany 1995.
  • Training on Drug safety-Behring werke AG Marburg/Germany 1994.